Skip to main content
. 2021 Sep 22;6(18):e150453. doi: 10.1172/jci.insight.150453

Figure 3. Molecular characteristics of pancreatic cancer patients with SWI/SNF alterations with and without immunotherapy.

Figure 3

Molecular analysis of each patient (ID). Orange boxes represent point mutations, blue boxes are deletions, red boxes are insertions, green boxes are gain-of-function (GOF), and purple boxes are fusions. KRAS mutations are described as none (X) or the specified point mutation. Tumor mutation burden (TMB) is described by mutations per megabase (mut/Mb) or none (X). PD-L1 is stratified on the scale: low (0%–1%), intermediate (2%–49%), high (50%+), or none (X) using the Dako 22C3 pharmDx qualitative immunohistochemical assay of tumor cells (38). The total number of genes analyzed per patient tumor sample is specified.